| Title | Cidofovir for BK Virus-Associated Hemorrhagic Cystitis: A Retrospective Study. | | Author(s) | Cesaro S, Hirsch HH, Faraci M, Owoc-Lempach J, Beltrame A, Tendas A, Baltadakis I, Dalle JH, Koc Y, Toporski J, Styczynski J, Yesilipek MA, Heinz W, Caniglia M, Rascon J, Fauser AA, Michallet M, Lopez-Corral L, Neuburger S, Tridello G, Einsele H, European Group for Blood and Marrow Transplantation | | Institution | University of Padua, Padua, 2Institute G. Gaslini, Genoa, and 3Policlinico Tor Vergata, 4Sant Eugenio Hospital, and 5Bambino Gesù Hospital, Rome, Italy; 6Division of Infectious Diseases & Hospital Epidemiology, University Hospital, and Transplantation Virology, Department of Biomedicine, Institute for Medical Microbiology, Basel, Switzerland; 7Wroclaw Medical University, Wroclaw, and 8University Hospital, Bydgoszcz, Poland; 9Evangelismos Hospital, Athens, Greece; 10Hôpital Robert Debre, Paris, and 11Hopital E. Herriot, Lyon, France; 12Medical Park Hospitals and 13Akdeniz University Medical School, Antalya, Turkey; 14University Hospital, Lund, Sweden; 15Medizinische und Poliklinik II, Würzburg, 16Klinik für Knochenmarktransplantation, Idar-Oberstein, and 17Charité Universitätsmedizin Berlin, Berlin, Germany; 18Hospital Clínico, Salamanca, Spain; and 19Vilnius University Childrens Hospital, Vilnius, Lithuania. | | Source | Clin Infect Dis 2009 Jun 12. | | Abstract | Background. BK virus-associated hemorrhagic cystitis (BKV-HC) is a severe complication after allogeneic hematopoietic stem cell transplantation (HSCT), but antiviral treatment for this condition has not been evaluated. Methods. We conducted a retrospective survey on the safety and outcome of cidofovir treatment for patients with BKV-HC in centers affiliated with the European Group for Blood and Marrow Transplantation.
Results. From 1 April 2004 to 31 December 2007, 62 patients received a diagnosis of BKV-HC after a median interval of 35 days after HSCT (range, 3-577 days). Fifty-seven patients (92%) received intravenous cidofovir, whereas 5 patients received cidofovir intravesically. Complete response (CR) was recorded in 38 (67%) of 57 patients with HC treated with intravenous cidofovir, whereas partial response (PR) was documented in 7 patients (12%). CR was documented in 3 patients and PR in 1 patient with HC treated with intravesical cidofovir. A reduction of 1-3 logs in BKV load was documented in 8 of the 10 patients achieving CR. Mild-to-moderate toxic effects were recorded in 18 of 57 patients who received intravenous cidofovir administration. In a multivariate analysis, the factors significantly associated with response to cidofovir were the stem cell source ([Formula: see text]) and the use of total body irradiation ([Formula: see text]). After a median follow-up of 287 days, overall survival and total treatment-related mortality rates were 63% and 40% for patients achieving CR, compared with 14% and 72% for patients with PR or no response to cidofovir, respectively ([Formula: see text] and [Formula: see text], respectively).
Conclusions. Cidofovir may be a potentially effective therapy for BKV-HC, but evidence supporting its use requires randomized controlled trials. | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 19522651 |
|
